Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators

Plain-language summary

This study examined quercetin, a compound that influences the CFTR protein linked to cystic fibrosis, and its effect on electrical measurements in the nose (nasal potential difference). It enrolled people aged 8 to 65 without a lung flare-up in the previous two weeks. It was carried out in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

University of Alabama at Birmingham

Intervention

quercetin

Start date

3/1/2010

Estimated completion

11/1/2011

Countries

United States

Related genes

Locations

• Birmingham, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* 8-65 years old
* absence of pulmonary exacerbation in the last 2 weeks
* willingness to perform nasal potential difference measurement

Exclusion Criteria:

* Need for chronic oxygen supplementation
* positive for B. cepecia within the last year
* active participation in another interventional trial utilizing ion transport modulators
* interfering medical conditions
* pregnant females